Skip to main content
SpringerLink
Log in

Insulin glargine provides basal insulin requirements in the management of diabetes mellitus

  • Disease Management
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. McKeage K, Goa KL. Insulin glargine: a review of its therapeutic use as a long-acting agent for the management of type 1 and 2 diabetes mellitus. Drugs 2001; 61(11): 1599–1624

    Article  PubMed  CAS  Google Scholar 

  2. Hermann LS. Optimising therapy for insulin-treated type 2 diabetes mellitus. Drugs Aging 2000 Oct; 17(4): 283–94

    Article  PubMed  CAS  Google Scholar 

  3. Rosskamp RH, Park G. Long-acting insulin analogs. Diabetes Care 1999; 22 Suppl. 2: B109–13

    PubMed  Google Scholar 

  4. Lepore M, Pampanelli S, Fanelli C, et al. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes 2000 Dec; 49: 2142–8

    Article  PubMed  CAS  Google Scholar 

  5. Mohn A, Strang S, Wernicke-Panten K, et al. Nocturnal glucose control and free insulin levels in children with type 1 diabetes by use of the long-acting insulin HOE 901 as part of a three-injection regimen. Diabetes Care 2000 Apr; 23: 557–9

    Article  PubMed  CAS  Google Scholar 

  6. Hershon K, Blevins T, Donley D, et al. Lower fasting blood glucose (FBG) and less symptomatic hypoglycemia with QD insulin glargine (Lantus) compared to BID NPH in subjects with type 1 diabetes [abstract 466-P]. Diabetes 2001 Jun; 50 Suppl. 2: 116–7

    Google Scholar 

  7. Ratner RE, Hirsch IB, Neifing JL, et al. Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. Diabetes Care 2000 May; 23: 639–43

    Article  PubMed  CAS  Google Scholar 

  8. Standl E. Results of an international, multicentred, randomised 28 week study for the comparison of glargine insulin (HOE 901) and NPH insulin in the intensified treatment (ICT) of type 1 diabetes [abstract no. pFr107]. Exp Clin Endrocrinol Diabetes 2000; 108 Suppl. 1: 159

    Google Scholar 

  9. Schoenle E. Insulin glargine (HOE 901) lowers fasting blood glucose in children with type I diabetes mellitus without increasing the risk of hypoglycaemia [abstract no. 883]. Diabetologia 1999; 42 Suppl. 1: A235

    Google Scholar 

  10. Fonseca V, Bell D, Mecca T. Less symptomatic hypoglycemia with bedtime insulin glargine (Lantus) compared to bedtime NPH insulin in patients with type 2 diabetes [abstract no. 449-P]. Diabetes 2001 Jun; 50 Suppl. 2: 112–3

    Google Scholar 

  11. Rosenstock J, Schwartz SL, Clark C, et al. Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin. Diabetes Care 2001 Apr; 24(4): 631–6

    Article  PubMed  CAS  Google Scholar 

  12. Raskin P, Klaff L, Bergenstal R, et al. A 16-week comparison of the novel insulin analog insulin glargine (HOE 901) and NPH human insulin used with insulin lispro in patients with type 1 diabetes. Diabetes Care 2000 Nov; 23: 1666–71

    Article  PubMed  CAS  Google Scholar 

  13. Rosenstock J. Management of type 2 diabetes mellitus in the elderly: special considerations. Drugs Aging 2001; 18(1): 31–44

    Article  PubMed  CAS  Google Scholar 

  14. Rosenstock J, Schwartz S, Clark C, et al. Efficacy and safety of HOE901 (insulin glargine) in subjects with type 2 DM: a 28-week randomized, NPH insulin-controlled trial [abstract]. Diabetes 1999; 42 Suppl. 1: A100

    Google Scholar 

  15. Buse JB. Overview of current therapeutic options in type 2 diabetes: rationale for combining oral agents with insulin therapy. Diabetes Care 1999; 22 Suppl. 3: C65–70

    PubMed  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Insulin glargine provides basal insulin requirements in the management of diabetes mellitus. Drugs Ther. Perspect 18, 7–9 (2002). https://doi.org/10.2165/00042310-200218070-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-200218070-00003

Keywords

Search

Navigation